These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8497922)

  • 1. A weekly schedule of epirubicin in pretreated advanced breast cancer.
    Barni S; Archili C; Lissoni P; Paolorossi F; Crispino S; Tancini G
    Tumori; 1993 Feb; 79(1):45-8. PubMed ID: 8497922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: a high-activity, dose-dense weekly regimen for advanced breast cancer.
    Nisticò C; Garufi C; Barni S; Frontini L; Gallà DA; Giannarelli D; Vaccaro A; D'Ottavio AM; Terzoli E
    Ann Oncol; 1999 Aug; 10(8):937-42. PubMed ID: 10509155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly epirubicin in advanced breast cancer.
    Tucci E; Algeri R; Guarnieri A; Pepi F; Sapio L; Bastreghi G; Pirtoli L
    Tumori; 1988 Dec; 74(6):689-92. PubMed ID: 3232214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial.
    Gasparini G; Dal Fior S; Panizzoni GA; Favretto S; Pozza F
    Am J Clin Oncol; 1991 Feb; 14(1):38-44. PubMed ID: 1987737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose epirubicin as a single agent in the treatment of patients with advanced breast cancer. A Hellenic Co-operative Oncology Group study.
    Fountzilas G; Skarlos D; Pavlidis NA; Makrantonakis P; Tsavaris N; Kalogera-Fountzila A; Giannakakis T; Beer M; Kosmidis P
    Tumori; 1991 Jun; 77(3):232-6. PubMed ID: 1862551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration.
    Blomqvist C; Elomaa I; Rissanen P; Hietanen P; Nevasaari K; Helle L
    J Clin Oncol; 1993 Mar; 11(3):467-73. PubMed ID: 8445422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support in advanced breast cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase II study.
    Frasci G; D'Aiuto G; Comella P; Thomas R; Capasso I; Di Bonito M; Rivellini F; Carteni G; De Lucia L; Maiorino L; D'Aniello R; Frezza P; Lapenta L; Comella G
    Breast Cancer Res Treat; 2000 Jul; 62(2):87-97. PubMed ID: 11016746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer.
    Gamucci T; D'Ottavio AM; Magnolfi E; Barduagni M; Vaccaro A; Sperduti I; Moscetti L; Belli F; Meliffi L
    Br J Cancer; 2007 Oct; 97(8):1040-5. PubMed ID: 17940499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer.
    Hortobagyi GN; Yap HY; Kau SW; Fraschini G; Ewer MS; Chawla SP; Benjamin RS
    Am J Clin Oncol; 1989 Feb; 12(1):57-62. PubMed ID: 2643296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly epirubicin plus lonidamine in advanced breast carcinoma.
    Nisticò C; Garufi C; Milella M; D'Ottavio AM; Vaccaro A; Fabi A; Terzoli E
    Breast Cancer Res Treat; 1999 Aug; 56(3):233-7. PubMed ID: 10573114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.
    Frasci G; D'Aiuto G; Comella P; Apicella A; Thomas R; Capasso I; Di Bonito M; Cartenì G; Biglietto M; De Lucia L; Maiorino L; Piccolo S; Bianchi U; D'Aniello R; Lapenta L; Comella G
    Breast Cancer Res Treat; 1999 Aug; 56(3):239-52. PubMed ID: 10573115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study.
    Nielsen D; Dombernowsky P; Larsen SK; Hansen OP; Skovsgaard T
    Cancer Chemother Pharmacol; 2000; 46(6):459-66. PubMed ID: 11138459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly paclitaxel with epirubicin as second-line therapy of metastatic breast cancer: results of a clinical phase II study.
    Köhler U; Olbricht SS; Fuechsel G; Kettner E; Richter B; Ridwelski K
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-40-S17-43. PubMed ID: 9374091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epirubicin in breast cancer patients with liver metastases and abnormal liver biochemistry: initial weekly treatment followed by rescheduling and intensification.
    Twelves CJ; Richards MA; Smith P; Rubens RD
    Ann Oncol; 1991 Oct; 2(9):663-6. PubMed ID: 1742222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group.
    Brufman G; Colajori E; Ghilezan N; Lassus M; Martoni A; Perevodchikova N; Tosello C; Viaro D; Zielinski C
    Ann Oncol; 1997 Feb; 8(2):155-62. PubMed ID: 9093724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of high dose epirubicin in combination with cyclophosphamide in patients with advanced breast cancer.
    Levi JA; Beith JM; Snyder RD; Tattersall MH; Bell D; Wheeler H
    Aust N Z J Med; 1995 Oct; 25(5):474-8. PubMed ID: 8588767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group study.
    Fountzilas G; Athanassiades A; Giannakakis T; Briasoulis E; Bafaloukos D; Kalogera-Fountzila A; Onienaoum A; Kalofonos H; Pectasides D; Andreopoulou E; Bamia C; Kosmidis P; Pavlidis N; Skarlos D
    Ann Oncol; 1997 Dec; 8(12):1213-20. PubMed ID: 9496386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage treatment with epirubicin and/or paclitaxel in metastatic breast cancer patients relapsed after high-dose chemotherapy with peripheral blood progenitor cells.
    Tartarone A; Sirotovà Z; Aieta M; Lelli G
    Tumori; 2001; 87(3):134-7. PubMed ID: 11504366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
    De Placido S; Lauria R; Carlomagno C; Perrone F; De Laurentiis M; Gallo C; Martignetti A; Bellelli T; Limite G; Petrella G; Bianco AR
    Int J Oncol; 1999 Aug; 15(2):339-46. PubMed ID: 10402245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
    Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
    Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.